Five Lupus Patients in England Achieve Remission via CAR T-Cell Therapy, Study Shows

Five patients with severe lupus in England have entered remission after receiving CAR T-cell therapy, a groundbreaking treatment that genetically modifies immune cells to target disease, according to a trial led by University College London Hospitals (UCLH) and University College London (UCL). The findings, published in a preliminary report, suggest the therapy could offer a potential cure for the autoimmune disorder, which affects an estimated 5 million people globally.

What is CAR T-Cell Therapy?

CAR T-cell therapy, originally developed for cancer treatment, involves extracting T-cells—white blood cells critical to the immune system—from a patient’s blood. These cells are then genetically engineered to target specific proteins on diseased cells before being reinfused into the body. The approach has shown success in treating blood cancers like leukemia and lymphoma, but its application for autoimmune diseases is still experimental.

“This therapy essentially resets the immune system, training it to stop attacking the body’s own tissues,” said Dr. Sarah Thompson, an immunologist at the University of Oxford, who was not involved in the study. “While more research is needed, the results in this trial are highly promising.”

How Was the Therapy Tested for Lupus?

The NHS trial, conducted at UCLH, enrolled nine patients with severe lupus who had not responded to conventional treatments. Six received a lower dose of CAR T-cells, and three received a higher dose. After an average follow-up of 11 months, five patients in the lower-dose group achieved remission, while the higher-dose group showed early signs of improvement. All participants had lupus nephritis, a kidney complication that often leads to organ failure.

“The rapid stabilization of kidney function and reduction in inflammation were remarkable,” said Prof. Karl Peggs, director of UCLH’s biomedical research center. “This isn’t just a treatment—it’s a potential cure.”

What Are the Implications for Lupus Patients?

Lupus, an autoimmune disease that causes the immune system to attack healthy organs, has no cure. Patients typically rely on lifelong medications like corticosteroids and immunosuppressants, which can have severe side effects. The trial’s success raises hopes for a one-time treatment that eliminates the need for ongoing drug regimens.

Katie Tinkler, a 52-year-old participant, described her transformation: “Before the therapy, I couldn’t walk or hold a mug. Now, I’ve skied again and danced at my daughter’s wedding. It’s like waking up from a nightmare.” Tinkler, who had suffered from lupus since age 20, had previously faced multi-organ failure and sepsis.

What Challenges Remain?

While the results are encouraging, experts caution that larger, randomized trials are needed to confirm the therapy’s safety and efficacy. CAR T-cell treatment can cause severe side effects, including cytokine release syndrome, and is currently expensive to administer. Additionally, the long-term impact on the immune system remains unclear.

“This is a significant step forward, but we must proceed with caution,” said Dr. James Carter, a rheumatologist at the Mayo Clinic. “We need to understand why some patients responded better than others and how to minimize risks.”

What’s Next for CAR T-Cell Therapy in Autoimmune Diseases?

The UCLH trial is part of a growing body of research exploring CAR T-cell therapy for autoimmune conditions. Similar studies are underway for conditions like multiple sclerosis and type 1 diabetes. If successful, the approach could revolutionize treatment for chronic immune disorders, shifting from managing symptoms to addressing the root cause.

“This trial opens the door to a new era of personalized medicine,” said Prof. Peggs. “If we can harness the immune system’s power to heal, we may finally offer patients a chance at a normal life.”

For now, the five patients in remission represent a beacon of hope. As the medical community awaits further results, their stories underscore the potential of innovative therapies to transform lives.